Erratum to "MRI gadolinium-based contrast agents. Radiologists beware!" [Ann Pharm Fr 2009;67:335-9] (DOI:10.1016/j.pharma.2009.06.002);MRI gadolinium-based contrast agents. Radiologists beware!

Annales Pharmaceutiques Francaises

Volumn 67, Issue 5, 2009, Pages 335-339

  Goulle J P ^a,b   Cattaneo A ^c   Saussereau, E ^a   Mahieu, L ^a   Guerbet, M ^b   Lacroix, C ^a  

^a LE HAVRE HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c hôpital et institut de soins infirmiers   (France)

Author keywords

Gadolinium; Nephrogenic systemic fibrosis

Indexed keywords

CHELATE; CONTRAST MEDIUM; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID;

ARTICLE; ATHEROSCLEROSIS; CHRONIC INFLAMMATION; CHRONIC KIDNEY DISEASE; CONTRAST ENHANCEMENT; DRUG APPROVAL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RELEASE; DRUG STABILITY; EUROPE; FOOD AND DRUG ADMINISTRATION; GLOMERULUS FILTRATION RATE; HEALTH CARE ORGANIZATION; HUMAN; HYPERPHOSPHATEMIA; LIMB SWELLING; LIVER NECROSIS; METABOLIC ACIDOSIS; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; RADIOLOGIST; RISK ASSESSMENT; SIDE EFFECT; SIGNAL DETECTION; SKIN BIOPSY; SPLEEN DISEASE; UNITED STATES;

EID: 68749112452     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pharma.2009.10.001     Document Type: Erratum

References (21)

1. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. Ann Rheum Dis 67 (2008) 66-69
2. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 21 (2006) 1104-1108
3. Idée J.M., Port M., Medina C., Lancelot E., Fayoux E., Ballet S., et al. Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: a critical review. Toxicology 248 (2008) 77-88
4. Morcos S.K., and Thomsen H.S. Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract 110 (2008) 24-31
5. Morcos S.K. Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition?. Br J Radiol 80 (2007) 73-76
6. Morcos S.K. Extracellular gadolinium contrast agents: differences in stability. Eur J Radiol 66 (2008) 175-179
7. Idée J.M., Port M., Raynal I., Schaefer M., Le Greneur S., and Corot C. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review. Fundam Clin Pharmacol 20 (2006) 563-576
8. Thomsen H.S., Marchmann P., and Logager V.B. Update on nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 16 (2008) 551-560
9. Perazella M.A. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. Curr Drug Saf 3 (2008) 67-75
10. Grebe S.O., Borrmann M., Altenburg A., Wesselman U., Hein D., and Haage P. Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure. Clin Exp Nephrol 12 (2008) 403-406
11. Saussereau E., Lacroix C., Cattaneo A., Mahieu L., and Goullé J.P. Hair and fingernail gadolinium ICP-MS contents in an overdose case associated with nephrogenic systemic fibrosis. Forensic Sci Int 176 (2008) 54-57
12. Shabana W.M., Cohan R.H., Ellis J.H., Hussain H.K., Francis I.R., Su L.D., et al. Nephrogenic systemic fibrosis: a report of 29 cases. AJR Am J Roentgenol 190 (2008) 736-741
13. Lauenstein T.C., Salman K., Morreira R., Tata S., Tudorascu D., Baramidze G., et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 26 (2007) 1198-1203
14. Nainani N., and Panesar M. Nephrogenic systemic fibrosis. Am J Nephrol 29 (2009) 1-9
15. Agarwak R., Brunelli S.M., Williams K., Mitchell M.D., Feldman H.I., and Umscheid C.A. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 24 (2009) 856-863
16. Marckmann P., Skov L., Rossen K., Dupont A., Damholt M.B., Heaf J.G., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17 (2006) 2359-2362
17. Broome D.R. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 66 (2008) 230-234
18. Marckmann P., Skov L., Rossen K., Heaf J.G., and Thomsen H.S. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22 (2007) 3174-3178
19. Version 7.0. August 2008. Available at www.esur.org.
20. Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol. 5 (2008) 45-52
21. Ortega L., Contreras G., and Lenz O. Nephrogenic fibrosing dermopathie or nephrogenic systemic fibrosis? What we know and what we have to learn. Nefrologia 29 (2009) 109-117